Express Healthcare
Home  »  News  »  AstraZeneca-Merck’s Lynparza wins EU approval for pancreatic cancer

AstraZeneca-Merck’s Lynparza wins EU approval for pancreatic cancer

0 86
Read Article

The approval was based on results from a late-stage trial in which Lynparza nearly doubled the lifespan of patients

AstraZeneca and Merck & Co said their blockbuster cancer treatment Lynparza won approval in the European Union for treating patients with a form of pancreatic cancer.

The approval was based on results from a late-stage trial in which Lynparza nearly doubled the lifespan of patients without disease progression or death when compared with placebo.

Lynparza, which can now be used to treat patients with a form of BRCA-mutated metastatic pancreatic cancer, leads a class of drugs known as PARP inhibitors that stop cancer cells from repairing themselves after being damaged by chemotherapy.

The approval comes more than a month after the drug received a positive recommendation from the European Medicines Agency for the same indication.

Lynparza, which can now be used to treat patients with a form of BRCA-mutated metastatic pancreatic cancer, leads a class of drugs known as PARP inhibitors that stop cancer cells from repairing themselves after being damaged by chemotherapy.

The approval comes more than a month after the drug received a positive recommendation from the European Medicines Agency for the same indication.

Lynparza became the first marketed PARP drug with a US approval for ovarian cancer in 2014 and is key to AstraZeneca’s push in oncology and sustaining the company’s turnaround.

Leave A Reply

Your email address will not be published.

Attend an exclusive webinar to know more about biomarkers in diagnosis & therapy management of heart failure.
Register Now
close-image
 Introducing Smart Autoinjector: Changing the paradigm of usability, cost & size
Know More?
close-image
Are you looking for ICP-MS which can increase productivity and remove time trap from your analysis?
Know More
close-image
The Radiology Conclave : Embrace the new normal
Register Now
close-image